Depyrogenated Sterile Empty Vials Market Report 2025

The depyrogenated sterile empty vials market size has grown strongly in recent years. It will grow from $3.63 billion in 2024 to $3.83 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to rise in pharmaceutical manufacturing, stringent regulatory standards, focus on drug stability and purity, increase in contract manufacturing, expansion of clinical trials, introduction of high-value biologics, focus on patient safety, shift towards ready-to-use components.

The depyrogenated sterile empty vials market size is expected to see strong growth in the next few years. It will grow to $5.25 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to focus on advanced drug delivery systems, increasing regulatory emphasis on container closure integrity, rise in personalized medicine approaches, expansion of biomanufacturing facilities, focus on sustainable packaging, digitalization of supply chain management, demand for high-value oncology drugs. Major trends in the forecast period include single-use technologies, biological drug development, quality by design (QBD) approaches, biodegradable and sustainable materials, digitalization in supply chain management, smart packaging technologies, advancements in aseptic filling technologies, collaborations and partnerships,.

The rising prevalence of infectious diseases worldwide is expected to drive the growth of the depyrogenated sterile empty vials market. Infectious diseases are conditions caused by harmful microorganisms such as bacteria, viruses, parasites, and fungi. Depyrogenated sterile vials are used for storing injectable medications involved in the treatment of these infectious diseases. Furthermore, depyrogenated sterile empty vials are also utilized for collecting laboratory samples. For example, in February 2024, the Health Security Agency, a UK-based government agency, reported a 10.7% increase in tuberculosis (TB) cases in England in 2023 compared to 2022. The number of cases grew from 4,380 in 2022 to 4,850 in 2023. As a result, the increasing prevalence of infectious diseases globally is expected to boost the growth of the depyrogenated sterile empty vials market.

The increase in the geriatric population is expected to drive the growth of the depyrogenated sterile empty vials market in the future. The geriatric population refers to elderly individuals aged 65 years and older. Depyrogenated sterile empty vials are used in this population to ensure medication safety and prevent infections, reducing the risk of pyrogenic reactions, which can cause fever and other adverse effects, particularly in older individuals. For example, in October 2022, according to the World Health Organization, a US-based specialized health agency, 1 in 6 people globally will be 60 or older by 2030, and the number of individuals in this age group will double to 2.1 billion by 2050. Additionally, in June 2021, according to the UK Parliament's House of Commons Library, a UK-based information resource, by 2043, the senior population in the UK is expected to rise, making up 24% of the total population (17.4 million people). Therefore, the growing geriatric population is fueling the growth of the depyrogenated sterile empty vials market.

Technological advancements have become a key trend gaining traction in the depyrogenated sterile empty vials market. Leading companies in the market are focusing on integrating advanced technologies into depyrogenated sterile empty vials to improve quality and maintain their competitive position. For example, in November 2022, Gerresheimer AG, a Germany-based drug packaging company, in collaboration with Stevanato Group S.p.A., an Italy-based provider of drug containment, delivery, and diagnostic solutions, launched the EZ-fill Smart platform. This new Ready-To-Fill solution for the global vial market aims to enhance drug packaging quality, lower total cost of ownership (TCO), and reduce lead times for customers. As an evolution of Stevanato Group's pioneering EZ-fill platform, EZ-fill Smart introduces key improvements that can significantly enhance customer product offerings, addressing the increasing demand for ready-to-use vials.

Leading companies in the depyrogenated sterile empty vials market are focusing on product innovation, such as Ready-to-Use (RTU) sterile 100 ml molded glass vials, to gain a competitive advantage. These vials are specifically designed for packaging high-value parenteral drugs in large volumes. For example, in March 2022, SGD Pharma, an India-based company specializing in glass pharmaceutical packaging services, launched Ready-to-Use (RTU) sterile 100 ml molded glass vials. These vials feature no glass-to-glass contact, reducing particle generation to enhance patient safety. They are compatible with various injectable applications and are sterile and depyrogenated, ensuring they are free from contaminants.

In June 2023, ALK-Abelló, Inc., a pharmaceutical company based in Denmark known for manufacturing sterile empty vials, entered into a strategic partnership with Galenova Inc., a Canada-based pharmaceutical company. Through this collaboration, ALK-Abelló, Inc. aims to enhance its distribution network by providing dependable and high-quality glass vials to pharmacies and hospitals throughout Canada. Galenova Inc. specializes in pharmaceutical products, including the provision of depyrogenated sterile empty vials. This partnership reflects a joint effort to strengthen the supply chain and deliver essential pharmaceutical components to the Canadian healthcare system.

Major companies operating in the depyrogenated sterile empty vials market are APG Pharma, Corning Inc., DWK Life Sciences, Nipro PharmaPackaging, Schott AG, Thermo Fisher Scientific, Gerresheimer AG, Stevanato Group, SGD Pharma, Merck KGaA, SiO2 Materials Science, Shandong Pharmaceutical Glass Co. Ltd., West Pharmaceutical Services Inc., Ompi Srl, AptarGroup Inc., Pacific Vial Manufacturing Inc., Adelphi Healthcare Packaging Limited, Acme Vial and Glass Company LLC, Amposan S.A., BMT Corporation, Cangzhou Four Stars Glass Co. Ltd., Ciron Drugs & Pharmaceuticals Pvt. Ltd., Zhejiang Pharmaceutical-Packaging Co. Ltd., Verpakkingsindustrie B.V.,

North America was the largest region in the depyrogenated sterile empty vials market in 2024. The regions covered in the depyrogenated sterile empty vials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the depyrogenated sterile empty vials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Depyrogenated sterile empty vials are borosilicate glass containers equipped with butyl-rubber stoppers and aluminum seals, designed for the storage of injectable drugs. Depyrogenation is a process that involves the removal of pyrogenic substances, including bacterial endotoxins, through the application of heat.

The main product types of depyrogenated sterile empty vials include 2 ml, 5 ml, 10 ml, 20 ml, and those exceeding 20 ml in volume. For example, a 2 ml vial refers to a container with a volume of 2 milliliters, commonly used for injectable drug storage. These vials are available in standard and large opening variations, typically used with aluminum seals. Depyrogenated sterile empty vials come in glass and plastic packaging, serving the needs of clinical labs, compounding labs, pharmaceutical companies, contract manufacturing organizations, and distributors.

The depyrogenated sterile empty vials market research report is one of a series of new reports that provides depyrogenated sterile empty vials market statistics, including depyrogenated sterile empty vials industry global market size, regional shares, competitors with a depyrogenated sterile empty vials market share, detailed depyrogenated sterile empty vials market segments, market trends and opportunities, and any further data you may need to thrive in the depyrogenated sterile empty vials industry. This depyrogenated sterile empty vials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The depyrogenated sterile empty vials market consists of sales of type I borosilicate glass, and molded and tabular glass depyrogenated sterile empty vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.